TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07488676: A Phase 1b/2 Open-label Study to Assess the Safety and Efficacy of ASP546C in Participants With CLDN18.2-expressing Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma, Pancreatic Adenocarcinoma o

Sponsor: Astellas Pharma Global Development, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$8,364,510

Rescue Site Savings

+$5,537,070

Unlock Full NCT07488676 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07488676 Rescue Dossier →